FDA Further Expands Approval of HCV Combo Drug Mavyret

Share this post

Mavyret is the first 8-week treatment approved for all treatment-naive adult and certain pediatric patients with any hepatitis C virus genotype, both without cirrhosis and with compensated cirrhosis.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply